ArticleCancer medicine2017
Metabolic characteristics of programmed cell death-ligand 1-expressing lung cancer on
Article in Cancer medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Predictive value of baseline metabolic tumor volume for non-small-cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.Frontiers in oncology · 2022Pooled it
- Prognostic value ofFrontiers in immunology · 2022Pooled it
- Predictive value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography for PD-L1 expression in non-small cell lung cancer: A systematic review and meta-analysis.Thoracic cancer · 2020Pooled it
- Standardized Uptake Values Derived fromContrast media & molecular imaging · 2018Pooled it
- Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/- UV1 telomerase vaccine.European journal of nuclear medicine and molecular imaging · 2025Trial
- PET/CT imaging for assessment of tumor immunotherapy response: a new perspective on tumor metabolic reprogramming and immune escape.La Radiologia medica · 2026Review
- Article
- Independent Testing of Published CT Models for PD-L1 Status in Non-Small Cell Lung Cancer.Radiology · 2026Article
- Article
- High PD-L1 expression correlates with lymph node metastasis in patients who have undergone radical surgery for primary pulmonary adenocarcinoma.Journal of thoracic disease · 2025Article
- Head-to-head comparison of peptide-based and nanobody-based radiotracers in detecting PD-L1 expression in non-small cell lung cancer.European journal of nuclear medicine and molecular imaging · 2025Article
- Using 18F-FDG PET/CT to predict programmed cell death ligand expression in non-small cell lung cancer via metabolic tumour heterogeneity.The British journal of radiology · 2025Article
- Predicting PD-L1 in Lung Adenocarcinoma UsingDiagnostics (Basel, Switzerland) · 2025Article
- The predictive value of total body PET/CT in high PD-L1 expression and immunotherapy in advanced non-small cell lung cancer patients.Frontiers in oncology · 2025Article
- Predicting programmed death-ligand 1 (PD-L1) expression with fluorine-18 fluorodeoxyglucose ([European radiology · 2024Article
- Texture Features ofJournal of clinical medicine · 2024Article
- Clinical feasibility study of early 30-minute dynamic FDG-PET scanning protocol for patients with lung lesions.EJNMMI physics · 2024Article
- Opportunities and challenges in combining immunotherapy and radiotherapy in esophageal cancer.Journal of cancer research and clinical oncology · 2023Review
- Research progress on the intrinsic non-immune function of PD-L1 in tumors (Review).Oncology letters · 2023Review
- FDG PET and CT radiomics in diagnosis and prognosis of non-small-cell lung cancer.Translational lung cancer research · 2022Article
Corrections and comments
- Commented on by
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) have been identified as novel targets of immunotherapy of lung cancer. In present study, we evaluated the metabolic characteristics of lung cancer by using
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.